No Data
Novo Nordisk Announced its Financial Report for the First Nine Months of 2024
Beneficiary of a weight-loss breakthrough: how to read Novo Nordisk's earnings?
SA Asks: How Will the U.S. Election Results Impact Healthcare Stocks?
Trending: Novo Nordisk Posts Higher 3Q Profit
Forecasting The Future: 7 Analyst Projections For Novo Nordisk
Novo Nordisk warns of the risks of compound generic drugs, stating that 10 people have died and over a hundred have been hospitalized.
①Novo-Nordisk's chief financial officer stated that 10 people have died after taking the compound generic weight-loss drug, with another 100 hospitalized. ②Novo-Nordisk has requested the FDA to list semaglutide in the "Provable Synthetic Difficulty List" to restrict generic production, and the company will continue to engage in dialogue with the FDA to address pharmaceutical accessibility issues.
No Data
No Data
Alen Kok : Oh